JP2016528255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528255A5 JP2016528255A5 JP2016534827A JP2016534827A JP2016528255A5 JP 2016528255 A5 JP2016528255 A5 JP 2016528255A5 JP 2016534827 A JP2016534827 A JP 2016534827A JP 2016534827 A JP2016534827 A JP 2016534827A JP 2016528255 A5 JP2016528255 A5 JP 2016528255A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pyridin
- hydroxy
- amino
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- 206010012289 Dementia Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- GRZMKKUGHIECFK-MNOVXSKESA-N (2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one Chemical compound C1([C@H](O)[C@@H](N)C(=O)N2CCCC2)=CC=NC=C1 GRZMKKUGHIECFK-MNOVXSKESA-N 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 201000007201 aphasia Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000020358 Learning disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000006888 Agnosia Diseases 0.000 claims 1
- 241001047040 Agnosia Species 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010010254 Concussion Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000018642 Semantic dementia Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 230000009514 concussion Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 claims 1
- 230000004907 flux Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361866155P | 2013-08-15 | 2013-08-15 | |
| US61/866,155 | 2013-08-15 | ||
| PCT/US2014/051007 WO2015023816A1 (en) | 2013-08-15 | 2014-08-14 | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528255A JP2016528255A (ja) | 2016-09-15 |
| JP2016528255A5 true JP2016528255A5 (https=) | 2017-09-21 |
| JP6486358B2 JP6486358B2 (ja) | 2019-03-20 |
Family
ID=51398940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534827A Active JP6486358B2 (ja) | 2013-08-15 | 2014-08-14 | （−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9242935B2 (https=) |
| EP (2) | EP3033327B1 (https=) |
| JP (1) | JP6486358B2 (https=) |
| CN (2) | CN108794386B (https=) |
| CA (1) | CA2921385C (https=) |
| DK (1) | DK3033327T3 (https=) |
| ES (1) | ES2664749T3 (https=) |
| HU (1) | HUE036381T2 (https=) |
| NO (1) | NO2960430T3 (https=) |
| PL (1) | PL3033327T3 (https=) |
| PT (1) | PT3033327T (https=) |
| SI (1) | SI3033327T1 (https=) |
| WO (1) | WO2015023816A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2921385C (en) | 2013-08-15 | 2021-10-19 | Allergan, Inc. | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
| US9992703B2 (en) * | 2016-04-04 | 2018-06-05 | Cisco Technology, Inc. | Insertion of management packet into a deterministic track |
| US20250161264A1 (en) * | 2022-02-11 | 2025-05-22 | Gilgamesh Pharmaceuticals, Inc. | (ampar-pam)-nmda receptor antagonist combination therapy for treatment of mental conditions and disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| AU2002348261A1 (en) * | 2001-11-26 | 2003-06-10 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| US20090088433A1 (en) * | 2005-01-26 | 2009-04-02 | Bertrand Leblond | Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| WO2008011483A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
| WO2008011478A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| JP2010520299A (ja) * | 2007-03-06 | 2010-06-10 | アラーガン、インコーポレイテッド | ３−アリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミド、３−ヘテロアリール−３−ヒドロキシ−２−アミノ−プロピオン酸アミドおよび関連化合物を使用する認知障害の処置方法 |
| US8173683B2 (en) * | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
| WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| CA2921385C (en) | 2013-08-15 | 2021-10-19 | Allergan, Inc. | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
-
2014
- 2014-08-14 CA CA2921385A patent/CA2921385C/en active Active
- 2014-08-14 CN CN201810276093.9A patent/CN108794386B/zh active Active
- 2014-08-14 DK DK14755535.3T patent/DK3033327T3/en active
- 2014-08-14 PL PL14755535T patent/PL3033327T3/pl unknown
- 2014-08-14 ES ES14755535.3T patent/ES2664749T3/es active Active
- 2014-08-14 US US14/459,551 patent/US9242935B2/en active Active
- 2014-08-14 PT PT147555353T patent/PT3033327T/pt unknown
- 2014-08-14 EP EP14755535.3A patent/EP3033327B1/en active Active
- 2014-08-14 SI SI201430670T patent/SI3033327T1/en unknown
- 2014-08-14 EP EP18150038.0A patent/EP3336079A1/en not_active Withdrawn
- 2014-08-14 JP JP2016534827A patent/JP6486358B2/ja active Active
- 2014-08-14 CN CN201480050583.7A patent/CN105555765B/zh active Active
- 2014-08-14 WO PCT/US2014/051007 patent/WO2015023816A1/en not_active Ceased
- 2014-08-14 HU HUE14755535A patent/HUE036381T2/hu unknown
-
2015
- 2015-06-26 NO NO15174003A patent/NO2960430T3/no unknown
- 2015-12-21 US US14/976,926 patent/US9540328B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512951A5 (https=) | ||
| JP2015511958A5 (https=) | ||
| RS52743B (sr) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciklo[2.2.2]okt-3-il)benzofuran-2-karboksamid, novi oblici soli i postupci za njihovu upotrebu | |
| JP2020502092A5 (https=) | ||
| JP2012521994A5 (https=) | ||
| JP5921576B2 (ja) | ピリドン誘導体を含む医薬組成物 | |
| IL255433B2 (en) | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine | |
| RU2014145682A (ru) | Органические соединения | |
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| HRP20141178T1 (hr) | Äśvrsti gama karbolin kondenziran sa supstituiranim heterociklusom | |
| CL2010000129A1 (es) | Compuestos derivados de benzazepinas fusionadas sustituidas, moduladores del receptor de acetilcolina; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de trastornos del snc tales como esquizofrenia, demencia, enfermedad del alzheimer, esclerosis multiple, entre otras. | |
| JP2005524675A (ja) | α７ニコチン性アセチルコリン受容体に対して親和性を有する１−アザビシクロＮ−ビアリールアミド | |
| JP2016528255A5 (https=) | ||
| JP2019534327A5 (https=) | ||
| SMT201700142T1 (it) | SALE DI CAMSILATO DI (1r, 1’R, 4R)-4-METOSSI-5’’-METIL-6’-[5-(PROP-1-IN-1-IL)PIRIDIN-3-IL]-3’H-DISPIRO[CICLOESANO-1,2’-INDEN-1’2’-IMIDAZOLO]-4’’-AMMINA E SUE FORME CRISTALLINE PER IL TRATTAMENTO DI PATOLOGIE A[BETA]-CORRELATE COME PER ESEMPIO LA MALATTIA DI ALZHEIMER | |
| JP2014205695A (ja) | アザアダマンタンエステルおよびカーバメート誘導体ならびにそれらの使用方法 | |
| WO2016029218A4 (en) | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation | |
| JP2012532125A5 (https=) | ||
| US8198296B2 (en) | Sub-type selective azabicycloalkane derivatives | |
| US20210198218A1 (en) | Compounds for therapeutic use | |
| JP5394939B2 (ja) | ４−置換アザアダマンタン誘導体およびそれの使用方法 | |
| ECSP10010397A (es) | Preparacion y separacion enantiomerica de 7-(3- piridinilo)-1,7-diazaspiro[4.4] nonano y formas novedosas de sal de la mezcla racemica y enantiomeros | |
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
| SI3033327T1 (en) | (-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE | |
| JP5859571B2 (ja) | ピリドン誘導体を含む医薬組成物 |